Science & Innovation Theaters

Science & Innovation Theaters provide a structured focus for participants to learn about specific products, therapeutic areas, and/or disease states in presentations given by company designated presenters.

Theaters will take place in The Exchange on Wednesday, Oct. 20.

Materials presented in theaters may be promotional and concentrate on a specific product, service, or therapeutic area. Therefore, these presentations are considered promotional and do not offer continuing education credit.

PIE Science & Innovation Theaters with a PIE logo include preapproval information exchange information. In accordance with federal laws and regulations, attendance at these sessions is restricted to payors, formulary committees, or other similar entity representatives with knowledge and expertise in health care economic analysis, carrying out responsibilities for the selection of drugs for coverage or reimbursement. Look for additional details on the AMCP PIE Information page.


Wednesday, Oct. 20 | Noon–12:30pm

Theater #1 
Thymic Stromal Lymphopoietin (TSLP) in Asthma: Examining the Evidence

Description: Asthma is a heterogeneous disease involving numerous cell types, mediators, and immune pathways.1 TSLP is a key epithelial cytokine with a main role in allergy and asthma pathophysiology.2 TSLP is at the top of the inflammatory cascade, where it initiates multiple downstream immune responses leading to the inflammation of the airway.3 This webinar will provide an overview of TSLP and its role in asthma inflammation.  

References: 1. Busse WW. Allergol Int. 2019;68:158-166. 2. Van Rompaey D, Verstraete K, Peelman F, et al. Sci Rep. 2017;7:17211. 3. Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM. Expert Opin Ther Targets. 2020;24:777-792. 

Faculty: Andrew W. Lindsley, MD, PhD, FAAAAI, Medical Director, US Medical Affairs, Amgen, Inc

Sponsored by Amgen Inc.

Theater #2
Advancing the Science of Medication Safety

Description: Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable pharmacists and health plans to improve outcomes and quality measures. TRHC’s MedWise® technology analyzes and compares how medications interact in aggregate, identifying patients at risk for adverse drug events. MedWise® provides clinical tools and actionable insights for pharmacists to prevent hospitalizations and emergency room visits, reducing the total cost of care. TRHC’s MedWise-certified pharmacists and network of more than 18,000 community pharmacies personalize medication regimens to improve efficacy, adherence, and reduce polypharmacy. Through a suite of solutions, TRHC offers vast opportunities for enhancing patient care and satisfaction for payers, providers, and other organizations.

Faculty: Kevin Boesen, PharmD, Chief Sales Officer, Tabula Rasa Healthcare
Kevin Barton, PharmD, MBA, VP, New Business Development & Pharmacy Consulting, Tabula Rasa Healthcare

Sponsored by Tabula Rasa


Wednesday, Oct. 20 | 12:45–1:15pm

Theater #1 
GOCOVRI® (amantadine) Extended Release Capsules: for Treatment of OFF Episodes and Dyskinesia in Patients with Parkinson’s Disease Taking Levodopa

Description: Review of the impact of Parkinson’s disease motor complications (dyskinesia and OFF time). GOCOVRI® (amantadine extended release) is the first and only FDA approved medication to treat dyskinesia and “Off” episodes in patients receiving levodopa therapy.  Earlier this year the FDA approved GOCOVRI for the treatment of OFF episodes in patients receiving levodopa based therapy.  This educational program will explore GOCOVRI’s clinical profile, including: clinical efficacy in reducing dyskinesia and OFF episodes, safety, 2-year open-label extension study results and dosing recommendations.

Faculty: Stuart Isaacson, MD, Director, Institute for Neurodegenerative Diseases of Florida, Parkinson’s Disease and Movement Disorders Center of Boca Raton, Alzheimer's and Memory Disorders Center of South Florida, Associate Professor of Neurology, FIU Herbert Wertheim College of Medicine

Sponsored by Adamas Pharmaceutical


Wednesday, Oct. 20 | 1:30–2pm

Theater #1
Assessing the Treatment Emergent Burden in BTKi Therapy: a Medicare Analysis in CLL (Chronic Lymphocytic Leukemia)

Description: While BTKs have greatly improved the prognosis of CLL/SLL, numerous adverse effects (AEs) have been reported which range from common to uncommon and from mild to severe. Atrial fibrillation (AF) is a severe AE associated with ibrutinib affecting 4% of users who developed grade 3 or greater AF or atrial flutter. New therapies are coming onboard to address the unmet need of high AE rates.  

We analyzed real world Medicare Advantage claims data to evaluate the rate of AEs among new ibrutinib starters and patterns of care after AE development. In particular, we compare the ibrutinib patients developing new AF to those who don’t develop AF as to their patterns of discontinuation and down dosing and their cost and medical utilization. 

Faculty: Kathryn V. Fitch, RN, Med, Principal, Healthcare Management Consultant

Sponsored by BeiGene LTD

Science & Innovation Theaters with a PIE logo include preapproval information exchange information. In accordance with federal laws and regulations, attendance at these sessions is restricted to payors, formulary committees, or other similar entity representatives with knowledge and expertise in health care economic analysis, carrying out responsibilities for the selection of drugs for coverage or reimbursement. Look for additional details on the AMCP PIE Information page.

Science & Innovation Theater sponsorship opportunities are available. Contact Laura Larson, assistant director, national meeting sales, at llarson@amcp.org  for more details.